Patrucco L, et al. - Among 97 patients with relapsing remitting multiple sclerosis (68% female [n = 66]; mean ± SD age, 30 ± 10.5 years; mean ± SD disease duration, 6.5 ± 3.1 years; mean ± SD Expanded Disability Status Scale, 3.5 ± 1; mean ± SD fingolimod use, 30 ± 13 months [range, 18–56 months]), researchers tested the safety and effectiveness of fingolimod in a real-world setting in Buenos Aires, Argentina. Included in August 2013 and June 2018 were relapsing remitting multiple sclerosis patients who had been prescribed fingolimod due to therapy failure and who had at least 24 months of follow-up. Investigators found that 82% were free from clinical relapses, and 85% were free from the progression of disability; 75% of patients remained free from new or newly enlarging T2 lesions, and 78% of patients were free from gadolinium-enhancing lesions. Data reported that the proportion of patients without disease activity was 54%. In a newly real-world setting, the effectiveness of fingolimod was consistent with information provided from phase III clinical trials.